Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CPT1A | P50416 | 3/20 | 0.32 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12702996 | 0.84 | ERN1 (0.36) | ERN1GSK3BCDK4CCND1ALDH1A1 | |
| SCHEMBL12658297 | 0.83 | POLB (0.33) | ERN1GSK3BCDK4CCND1ALDH1A1 | |
| SCHEMBL12658150 | 0.82 | POLB (0.34) | ERN1GSK3BCDK4CCND1ALDH1A1 | |
| SCHEMBL3760924 | 0.81 | ERN1 (0.32) | ERN1GSK3BCDK4CCND1 | |
| SCHEMBL10231566 | 0.78 | MAOB (0.35) | ERN1GSK3BALDH1A1CNR2CSNK2A2 | |
| SCHEMBL1900642 | 0.77 | GSK3B (0.39) | ERN1GSK3BCDK4CCND1ALDH1A1 | |
| SCHEMBL9883907 | 0.72 | MAOA (0.32) | — | |
| SCHEMBL12703203 | 0.72 | — | — | |
| SCHEMBL1901580 | 0.72 | GSK3B (0.35) | ERN1GSK3BCDK4CCND1ALDH1A1 | |
| SCHEMBL13960144 | 0.70 | GSK3B (0.40) | GSK3BCDK4CCND1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606254-B1 | 2,4,6-PHENYL SUBSTITUTED CYCLIC KETOENOLS | BAYER CROPSCIENCE AG (DE) | 2011-05-11 | — | — | EP | disclosed |
| US-20110092368-A1 | 2,4,6-Phenyl-substituted cyclic ketoenols | FISCHER REINER | 2011-04-21 | — | — | US | disclosed |
| US-20110092368-A1 | 2,4,6-Phenyl-substituted cyclic ketoenols | FISCHER REINER | 2011-04-21 | — | — | US | disclosed |
| US-7888285-B2 | 2,4,6-phenyl substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2011-02-15 | — | — | US | disclosed |
| US-7888285-B2 | 2,4,6-phenyl substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2011-02-15 | — | — | US | disclosed |
| US-20070015664-A1 | 2,4,6-Phenyl substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015664-A1 | 2,4,6-Phenyl substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015664-A1 | 2,4,6-Phenyl substituted cyclic ketoenols | CYP4X1, KDM4E, KCNE1 | ERN1 2587/4885GSK3B 138/4885CDK4 458/4885 |
| US-20110092368-A1 | 2,4,6-Phenyl-substituted cyclic ketoenols | CYP4X1, KDM4E, PDHX | ERN1 2748/4885GSK3B 201/4885CDK4 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.